The US market is currently closed. It will re-open at 13:30 tomorrow.
US Market
About Reviva Pharmaceuticals Holdings Inc
This is a clinical-stage biopharmaceutical company. Currently, it is working to develop drugs for problems in the central nervous system (CNS), respiratory system and metabolic diseases. They have two main drugs in development: RP5063 (also known as brilaroxazine) and RP1208. Brilaroxazine is being tested for various mental health conditions like schizophrenia, bipolar disorder, major depressive disorder, ADHD, Alzheimer’s disease and psychosis related to Parkinson’s disease. It's also being explored for respiratory issues like pulmonary arterial hypertension and idiopathic pulmonary fibrosis. RP1208 is a triple reuptake inhibitor (TRI).
Freetrade is your gateway to commission-free investing. Join over 1.6 million users using the Best online trading platform, as voted at the British Bank Awards for six years running.
Freetrade does not provide investment advice and individual investors should make their own decisions or seek independent advice. The value of investments can go down as well as up and you may receive back less than your original investment. Past performance is not a reliable indicator of future returns. Freetrade is a trading name of Freetrade Limited, which is a member firm of the London Stock Exchange and is authorised and regulated by the Financial Conduct Authority. Registered in England and Wales (no. 09797821).
© 2025 Freetrade, All rights reserved. The Apple logo is a trademark of Apple Inc. App Store is a service mark of Apple Inc. Google Play and the Google Play logo are trademarks of Google LLC.